Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
9.0
6.0
Journals
Cells
Special Issues
Genetic Regulation and Therapeutic Opportunities in Neurodegeneration and Neuroregeneration
share announcement

Genetic Regulation and Therapeutic Opportunities in Neurodegeneration and Neuroregeneration

A special issue of Cells (ISSN 2073-4409). This special issue belongs to the section "Cell and Gene Therapy".

Deadline for manuscript submissions: closed (15 January 2024) | Viewed by 1641

Special Issue Editor

Dr. Sung-Rae Cho

E-Mail Website
Guest Editor
Department of Rehabilitation Medicine, Yonsei University College of Medicine, Seoul 03722, Republic of Korea
Interests: genes; genetics; neurodegeneration; neuroregeneration; neural repair
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

Genetics is essential to the pathophysiological mechanisms of neurodegenerative or neurodevelopmental diseases, as it can cause or modify one’s susceptibility to sporadic diseases. The identification of disease-causing genes has led to advances in treatments that modify target genes and disease phenotypes. Recently, research our understanding of genetics and genomics as a personalized medicine in Parkinson’s disease, Huntington’s disease, amyotrophic lateral sclerosis and Alzheimer’s dementia, as well as other neurological diseases, has progressed. In addition, studies on ex vivo cell-based therapy or in vivo reprogramming therapy to induce the restoration of damaged central nervous systems have contributed to the development of regenerative medicine. Articles submitted to this Special Issue should include basic, clinical and translational studies that provide insights into the diagnosis, pathophysiology and treatment of neurological diseases. We invite you to submit your research, including strategies for neuroregeneration and neural repair and genetic regulation and genomic changes following various therapeutic treatments, such as stem cell-based therapy, in vivo cellular reprogramming, gene therapy, genome editing technology, pharmacologic treatment, physical exercise, environmental enrichment, magnetic stimulation, electrical stimulation, and so on.

Dr. Sung-Rae Cho
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cells is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • genes
  • genetics
  • neurodegeneration
  • neuroregeneration
  • neural repair

Published Papers (1 paper)

Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Review

18 pages, 772 KiB  
Review
In Vivo Reprogramming Using Yamanaka Factors in the CNS: A Scoping Review
by Han Eol Cho, Siwoo Lee, Jung Hwa Seo, Seong-Woong Kang, Won Ah Choi and Sung-Rae Cho
Cells 2024, 13(4), 343; https://doi.org/10.3390/cells13040343 - 15 Feb 2024
Viewed by 1454
Abstract
Central nervous system diseases, particularly neurodegenerative disorders, pose significant challenges in medicine. These conditions, characterized by progressive neuronal loss, have remained largely incurable, exacting a heavy toll on individuals and society. In recent years, in vivo reprogramming using Yamanaka factors has emerged as [...] Read more.
Central nervous system diseases, particularly neurodegenerative disorders, pose significant challenges in medicine. These conditions, characterized by progressive neuronal loss, have remained largely incurable, exacting a heavy toll on individuals and society. In recent years, in vivo reprogramming using Yamanaka factors has emerged as a promising approach for central nervous system regeneration. This technique involves introducing transcription factors, such as Oct4, Sox2, Klf4, and c-Myc, into adult cells to induce their conversion into neurons. This review summarizes the current state of in vivo reprogramming research in the central nervous system, focusing on the use of Yamanaka factors. In vivo reprogramming using Yamanaka factors has shown promising results in several animal models of central nervous system diseases. Studies have demonstrated that this approach can promote the generation of new neurons, improve functional outcomes, and reduce scar formation. However, there are still several challenges that need to be addressed before this approach can be translated into clinical practice. These challenges include optimizing the efficiency of reprogramming, understanding the cell of origin for each transcription factor, and developing methods for reprogramming in non-subventricular zone areas. Further research is needed to overcome the remaining challenges, but this approach has the potential to revolutionize the way we treat central nervous system disorders. Full article
(This article belongs to the Special Issue Genetic Regulation and Therapeutic Opportunities in Neurodegeneration and Neuroregeneration)
►▼ Show Figures

Figure 1

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-1
Back to TopTop